Evidence map›Paper›PMID 38035711›Full record

ArticleCancer genomics & proteomics2023

(S)-3-(3-Fluoro-4-Methoxybenzyl)-5,6,7-Trimethoxychroman-4-One Suppresses the Proliferation of Huh7 Cells by Up-regulating P21 and Inducing G

Haelim Yoon, Junho Lee, Sangil Kwon, Seung-Yong Seo, Sayeon Cho

Open access · diamondAbstract read
In one paragraph

Article in Cancer genomics & proteomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Haelim YoonCollege of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
Junho LeeCollege of Pharmacy, Chung-Ang University, Seoul, Republic of Korea.
Sangil KwonCollege of Pharmacy, Gachon University, Incheon, Republic of Korea.
Seung-Yong SeoCollege of Pharmacy, Gachon University, Incheon, Republic of Korea.
Sayeon ChoCollege of Pharmacy, Chung-Ang University, Seoul, Republic of Korea; sycho@cau.ac.kr.
Chung-Ang University · KRGachon University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimHepatocellular carcinoma (HCC) is a prevalent type of cancer worldwide. Although sorafenib is the only chemotherapy agent used for HCC, there is a need to discover a more potent anticancer agent with reduced side-effects. The compound, (S)-3-(3-fluoro-4-methoxybenzyl)-5,6,7-trimethoxychroman-4-one (FMTC), was designed to inhibit tubulin assembly but its specific mechanisms of action have not been previously investigated. Herein, we investigated the regulation mechanisms by which FMTC affects the proliferation of the HCC cell line, Huh7. MATERIALS AND

methodsThe effects of FMTC on cell viability and growth were analyzed in the HCC cell line, Huh7. Cell cycle and apoptosis regulated by FMTC were analyzed using flow cytometry. To verify the regulation of mRNA and protein expression of cell proliferation-related factors by FMTC in Huh7 cells, RT-qPCR and western blot analyses were employed.

resultsFMTC suppressed cell division dose-dependently by triggering cell cycle arrest at the G

conclusionFMTC inhibits the proliferation of human liver cancer cells by up-regulating p21, thereby inducing cell cycle arrest at the G

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsApoptosisCell Cycle CheckpointsCell DivisionCell Line, TumorCell ProliferationHumansantiproliferationFMTCG2/M-phase arrestHCCp21

Identifiers

PMID38035711
PMCPMC10687728
OpenAlexW4389206069

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.